Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

Publication date: Available online 29 October 2020Source: The Lancet NeurologyAuthor(s): Jerry S Wolinsky, Douglas L Arnold, Bruno Brochet, Hans-Peter Hartung, Xavier Montalban, Robert T Naismith, Marianna Manfrini, James Overell, Harold Koendgen, Annette Sauter, Iain Bennett, Stanislas Hubeaux, Ludwig Kappos, Stephen L Hauser
Source: The Lancet Neurology - Category: Neurology Source Type: research